Contrasting Interpace Biosciences (OTCMKTS:IDXG) & H-CYTE (OTCMKTS:HCYTD)

Institutional and Insider Ownership

5.7% of Interpace Biosciences shares are held by institutional investors. 5.2% of H-CYTE shares are held by company insiders. Comparatively, 5.5% of Interpace Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares H-CYTE and Interpace Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A
Interpace Biosciences	$38.73 million	0.24	$24.58 million	($0.02)	-106.00

Interpace Biosciences has higher revenue and earnings than H-CYTE.

Profitability

This table compares H-CYTE and Interpace Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
H-CYTE	-450.40%	N/A	-777.68%
Interpace Biosciences	63.46%	493.02%	137.46%

Risk & Volatility

H-CYTE has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Summary

Interpace Biosciences beats H-CYTE on 7 of the 9 factors compared between the two stocks.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.